We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

2784:TSEAlfresa Holdings Corporation Analysis

Data as of 2026-03-15 - not real-time

¥2,386.50

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Alfresa Holdings is trading at ¥2,386.5, which sits below its 20‑day and 50‑day SMAs of ¥2,536 and ¥2,527.9 but remains above the 200‑day SMA of ¥2,258.5, suggesting a short‑term pullback within a longer‑term uptrend. The RSI of 35.6 points to oversold conditions, while the MACD is in a bearish phase, creating mixed technical signals. Price is perched just above the identified support at ¥2,371 and faces resistance near the 52‑week high of ¥2,685.5, with a 30‑day volatility of 24.6% but a very low beta of 0.19, indicating limited market‑wide risk. The company delivers a solid 2.85% dividend yield on a payout ratio of 48.7%, backed by ample cash of ¥222.8 bn versus modest debt of ¥30 bn, reinforcing dividend sustainability. Despite modest revenue growth of 3.4% and thin margins (gross 7.1%, operating 1.6%), the stock trades at a PE of 17.6, well below the industry average of 26.2, and a price‑to‑book of 0.87, hinting at relative undervaluation. However, analysts’ target prices average ¥2,283, implying a potential downside of around 4.3% from current levels, and the low ROE of 6.9% tempers growth expectations.

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 6/10

Key Factors

  • Price near immediate support level
  • Bearish MACD despite oversold RSI
  • Limited upside given resistance and target price

Medium Term

1–3 years
Positive
Model confidence: 7/10

Key Factors

  • Attractive dividend yield with sustainable payout
  • PE well below industry average indicating relative cheapness
  • Low beta and stable liquidity supporting steady returns

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • Stable cash position and low leverage
  • Modest growth prospects and thin profit margins
  • Consistent dividend policy in a low‑risk healthcare segment

Key Metrics & Analysis

Financial Health

Revenue Growth3.40%
Profit Margin1.10%
P/E Ratio17.6
ROE6.88%
ROA1.42%
Debt/Equity6.04
P/B Ratio0.9
Industry P/E26.2

Technical Analysis

TrendBullish
RSI35.6
Support¥2,371.00
Resistance¥2,685.50
MA 20¥2,536.00
MA 50¥2,527.94
MA 200¥2,258.47
MACDBearish
VolumeStable
Fear & Greed Index72.88

Valuation

Target Price¥2,283.33
Upside/Downside-4.32%
GradeFair
TypeValue
Dividend Yield2.85%

Risk Assessment

Beta0.19
Volatility24.60%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.